AGL 40.21 Increased By ▲ 0.18 (0.45%)
AIRLINK 127.64 Decreased By ▼ -0.06 (-0.05%)
BOP 6.67 Increased By ▲ 0.06 (0.91%)
CNERGY 4.45 Decreased By ▼ -0.15 (-3.26%)
DCL 8.73 Decreased By ▼ -0.06 (-0.68%)
DFML 41.16 Decreased By ▼ -0.42 (-1.01%)
DGKC 86.11 Increased By ▲ 0.32 (0.37%)
FCCL 32.56 Increased By ▲ 0.07 (0.22%)
FFBL 64.38 Increased By ▲ 0.35 (0.55%)
FFL 11.61 Increased By ▲ 1.06 (10.05%)
HUBC 112.46 Increased By ▲ 1.69 (1.53%)
HUMNL 14.81 Decreased By ▼ -0.26 (-1.73%)
KEL 5.04 Increased By ▲ 0.16 (3.28%)
KOSM 7.36 Decreased By ▼ -0.09 (-1.21%)
MLCF 40.33 Decreased By ▼ -0.19 (-0.47%)
NBP 61.08 Increased By ▲ 0.03 (0.05%)
OGDC 194.18 Decreased By ▼ -0.69 (-0.35%)
PAEL 26.91 Decreased By ▼ -0.60 (-2.18%)
PIBTL 7.28 Decreased By ▼ -0.53 (-6.79%)
PPL 152.68 Increased By ▲ 0.15 (0.1%)
PRL 26.22 Decreased By ▼ -0.36 (-1.35%)
PTC 16.14 Decreased By ▼ -0.12 (-0.74%)
SEARL 85.70 Increased By ▲ 1.56 (1.85%)
TELE 7.67 Decreased By ▼ -0.29 (-3.64%)
TOMCL 36.47 Decreased By ▼ -0.13 (-0.36%)
TPLP 8.79 Increased By ▲ 0.13 (1.5%)
TREET 16.84 Decreased By ▼ -0.82 (-4.64%)
TRG 62.74 Increased By ▲ 4.12 (7.03%)
UNITY 28.20 Increased By ▲ 1.34 (4.99%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
BR100 10,086 Increased By 85.5 (0.85%)
BR30 31,170 Increased By 168.1 (0.54%)
KSE100 94,764 Increased By 571.8 (0.61%)
KSE30 29,410 Increased By 209 (0.72%)

LONDON: The Bill & Melinda Gates Foundation has given $23.6 million to US-based life science company Micron Biomedical to fund the first ever mass production of needle-free vaccine technology.

The technology works by delivering the vaccine via dissolvable microneedles attached to the skin on a patch-like device.

Global health experts have long argued for the potential of similar technology to boost the uptake of life-saving shots.

It is simpler to transport and administer than traditional injections, particularly in low-income countries where reaching all of the children who need vaccines remains challenging. But scaling up production has been a hurdle.

A trial in Gambia earlier this year showed that Micron’s device delivered the measles-rubella vaccine, produced by the Serum Institute of India, to adults, babies and toddlers as safely and effectively as syringes, and produced a similar immune response.

The technology “could help overcome some of the most substantial barriers to eradicating measles and rubella globally”, said James Goodson, senior scientist in the immunization division at the US Centers for Disease Control and Prevention (CDC), which has also partnered with Micron.

It reduces the need for a cold chain for distribution, and does not require a trained professional to give the vaccine. It could also help those with a fear of injections, the company said in a statement on Thursday.

The funding will support the development of a manufacturing facility to help make around 10 million devices annually, for larger clinical trials and then wider use, subject to approvals from regulatory authorities.

The company has had several other grants from Gates, to help deliver the technology to “underserved populations around the world”, Micron’s CEO Steven Damon said.

Comments

Comments are closed.